<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OL</journal-id>
<journal-title-group>
<journal-title>Oncology Letters</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-1074</issn>
<issn pub-type="epub">1792-1082</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ol.2017.7206</article-id>
<article-id pub-id-type="publisher-id">OL-0-0-7206</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Herbal compound Teng-Long-Bu-Zhong-Tang inhibits metastasis in human RKO colon carcinoma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Wei</surname><given-names>Meng-Meng</given-names></name>
<xref rid="af1-ol-0-0-7206" ref-type="aff">1</xref>
<xref rid="af2-ol-0-0-7206" ref-type="aff">2</xref>
<xref rid="af3-ol-0-0-7206" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author"><name><surname>Wang</surname><given-names>Shuang-Shuang</given-names></name>
<xref rid="af1-ol-0-0-7206" ref-type="aff">1</xref>
<xref rid="af2-ol-0-0-7206" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Jia-Lu</given-names></name>
<xref rid="af1-ol-0-0-7206" ref-type="aff">1</xref>
<xref rid="af2-ol-0-0-7206" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jin-Jun</given-names></name>
<xref rid="af4-ol-0-0-7206" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author"><name><surname>Yan</surname><given-names>Xia</given-names></name>
<xref rid="af1-ol-0-0-7206" ref-type="aff">1</xref>
<xref rid="af2-ol-0-0-7206" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>An</surname><given-names>Hong-Mei</given-names></name>
<xref rid="af5-ol-0-0-7206" ref-type="aff">5</xref></contrib>
<contrib contrib-type="author"><name><surname>Hu</surname><given-names>Bing</given-names></name>
<xref rid="af1-ol-0-0-7206" ref-type="aff">1</xref>
<xref rid="af2-ol-0-0-7206" ref-type="aff">2</xref>
<xref rid="c1-ol-0-0-7206" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-ol-0-0-7206"><label>1</label>Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China</aff>
<aff id="af2-ol-0-0-7206"><label>2</label>Institute of Traditional Chinese Medicine in Oncology, Shanghai Academy of Traditional Chinese Medicine, Shanghai 200032, P.R. China</aff>
<aff id="af3-ol-0-0-7206"><label>3</label>Beizhonghe Clinics, Qingdao, Shandong 266000, P.R. China</aff>
<aff id="af4-ol-0-0-7206"><label>4</label>Department of Plastic and Reconstructive Surgery, Shanghai Key Laboratory of Tissue Engineering, The Ninth People&#x0027;s Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200011, P.R. China</aff>
<aff id="af5-ol-0-0-7206"><label>5</label>Department of Science and Technology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China</aff>
<author-notes>
<corresp id="c1-ol-0-0-7206"><italic>Correspondence to</italic>: Dr Bing Hu, Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Road, Shanghai 200032, P.R. China, E-mail: <email>beearhu@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>12</month>
<year>2017</year></pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>10</month>
<year>2017</year></pub-date>
<volume>14</volume>
<issue>6</issue>
<fpage>7767</fpage>
<lpage>7772</lpage>
<history>
<date date-type="received"><day>30</day><month>08</month><year>2016</year></date>
<date date-type="accepted"><day>07</day><month>09</month><year>2017</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Wei et al.</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Metastasis is one of the primary obstacles to the successful treatment of colorectal cancer. Teng-Long-Bu-Zhong-Tang (TLBZT) is a modern Chinese herbal formula that may be useful in the treatment of metastatic colorectal cancer. The present study evaluated the effects of TLBZT on lung metastasis in human RKO colon carcinoma cells injected into mice via the tail vein. The results demonstrated that TLBZT inhibited the metastasis of human RKO colon carcinoma cells to the lungs. TLBZT downregulated the expression of LOX and hypoxia-inducible factor 1&#x03B1;. TLBZT also inhibited the expression of integrins &#x03B1;V and &#x03B2;3 and the phosphorylation of focal adhesion kinase. These results indicate that TLBZT inhibits the lung metastasis of RKO colon carcinoma by regulating the expression of multiple genes. The results of the present study provide a new basis for the management of colorectal cancer metastasis using treatments derived from Chinese herbs.</p>
</abstract>
<kwd-group>
<kwd>colorectal carcinoma</kwd>
<kwd>metastasis</kwd>
<kwd>lysyl oxidase</kwd>
<kwd>hypoxia-inducible factor 1&#x03B1;</kwd>
<kwd>integrins &#x03B1;V and &#x03B2;3</kwd>
<kwd>focal adhesion kinase</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Colorectal carcinoma is the third most common cancer in males and the second most common in females (<xref rid="b1-ol-0-0-7206" ref-type="bibr">1</xref>). Metastasis is the primary cause of treatment failure in patients with colorectal cancer and usually occurs in the liver, lungs and other organs due to the malignant characteristics of the disease (<xref rid="b2-ol-0-0-7206" ref-type="bibr">2</xref>,<xref rid="b3-ol-0-0-7206" ref-type="bibr">3</xref>). Current treatments of metastatic colorectal cancer include surgery, chemotherapy and targeted therapy, which uses small molecule-based drugs or monoclonal antibodies against abnormally expressed proteins that are essential for cancer cell growth, including anti-EGFR agents, e.g., cetuximab and panitumumab, in addition to anti-VEGF agents, e.g., bevacizumab and aflibercept (<xref rid="b4-ol-0-0-7206" ref-type="bibr">4</xref>). Due to unresectable metastatic lesions, only a small proportion of patients with metastatic colorectal cancer are eligible to undergo surgery (<xref rid="b5-ol-0-0-7206" ref-type="bibr">5</xref>,<xref rid="b6-ol-0-0-7206" ref-type="bibr">6</xref>). Furthermore, chemotherapy induces toxic side effects and targeted therapy is very expensive, meaning that few patients with metastatic colorectal cancer receive suitable treatment. Currently, the 5-year survival rate of patients with metastatic colorectal cancer is &#x003C;15&#x0025; (<xref rid="b7-ol-0-0-7206" ref-type="bibr">7</xref>,<xref rid="b8-ol-0-0-7206" ref-type="bibr">8</xref>). Therefore, it is necessary to develop a novel approach to treat and prevent metastasis in colorectal cancer.</p>
<p>Traditional Chinese medicine (TCM) may be used as a method of treating colorectal cancer. Syndrome differentiation-based treatment with TCM decoctions can alleviate symptoms, improve quality of life and immune function, produce synergistic effects alongside anti-cancer chemotherapy, prevent cancer recurrence and metastasis and prolong the survival time of patients with colorectal cancer (<xref rid="b9-ol-0-0-7206" ref-type="bibr">9</xref>,<xref rid="b10-ol-0-0-7206" ref-type="bibr">10</xref>). Based on the principles and practice of TCM, the formula, Teng-Long-Bu-Zhong-Tang (TLBZT) has been produced that may potentially be used to treat patients with colorectal cancer. Previous studies have suggested that TLBZT inhibits proliferation and induces apoptosis and senescence in colon cancer cells (<xref rid="b11-ol-0-0-7206" ref-type="bibr">11</xref>&#x2013;<xref rid="b13-ol-0-0-7206" ref-type="bibr">13</xref>).</p>
<p>Some of the herbs present in TLBZT have been studied. <italic>Actinidia chinensis</italic> and <italic>Duchesnea indica</italic> can inhibit cell proliferation in suspension, induce active oxygen production, activate caspase-3 and induce anoikis in colorectal cancer cells (<xref rid="b14-ol-0-0-7206" ref-type="bibr">14</xref>,<xref rid="b15-ol-0-0-7206" ref-type="bibr">15</xref>). Anoikis is a form of programmed cell death elicited when cells detach from the extracellular matrix (ECM) and is closely associated with the survival of tumor cells in a liquid environment, including the blood and lymph circulation. Therefore, inhibiting the growth of tumor cells in suspension and inducing anoikis may suppress cancer metastasis. Furthermore, <italic>Solanum nigrum</italic>, one of the herbs present in TLBZT, inhibits the proliferation, adhesion, migration and invasion of colorectal cancer cells (<xref rid="b16-ol-0-0-7206" ref-type="bibr">16</xref>). These observations suggest that TLBZT may inhibit the metastasis of colorectal cancer cells.</p>
<p>The present study evaluated the effect of TLBZT on colorectal cancer metastasis <italic>in vivo</italic>. The effects of TLBZT on the expression of the metastasis-associated genes, including lysyl oxidase (LOX), hypoxia-inducible factor 1&#x03B1; (HIF-1&#x03B1;), integrins &#x03B1;v and &#x03B2;3 and the phosphorylation of focal adhesion kinase (p-FAK), were also determined. The results demonstrated that TLBZT inhibits the metastasis of human RKO colon carcinoma cells to the lungs, downregulates the expression of LOX, HIF-1&#x03B1;, integrin &#x03B1;V and &#x03B2;3, and inhibits FAK phosphorylation.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Reagents</title>
<p>Dulbecco&#x0027;s Modified Eagle&#x0027;s medium (DMEM) and fetal bovine serum were obtained from Hyclone; GE Healthcare Life Sciences (Logan, UT, USA). The antibody against LOX was purchased from Novus Biologicals (Littleton, CO, USA) (cat. no. NB100-2527). The antibody against HIF-1&#x03B1; was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) (cat. no. sc-53546). Antibodies against integrins &#x03B1;V (cat. no. BS3513) and &#x03B2;3 (cat. no. BS1187), phosphorylated (p)-FAK (cat. no. BS4617), horseradish peroxidase (HRP)-conjugated-anti-rabbit IgG (cat. no. BS13278) and anti-Mouse IgG-HRP (cat. no. BS12478) were procured from Bioworld Technology, Inc. (St. Louis Park, MN, USA).</p>
</sec>
<sec>
<title>TLBZT extraction</title>
<p>The major herbs in the TLBZT formula (Chinese patent ZL200910197565.2) are: The roots of <italic>A. chinensis</italic> (30 g), <italic>S. nigrum</italic> (15 g), <italic>D. indica</italic> (15 g), <italic>Atractylodes macrocephala</italic> (9 g), <italic>Coix</italic> seed (30 g) and <italic>Viscum coloratum</italic> (15 g). All the aforementioned herbs were obtained from Longhua Hospital (Shanghai, China) in accordance with the amounts required for the TLBZT formula and decocted twice with 8-fold distilled water at 100&#x00B0;C for 1 h. The decoctions were merged, filtered and made up to a concentration of 1.5 g crude herb materials/ml water and stored at 4&#x00B0;C.</p>
</sec>
<sec>
<title>RKO cell culture</title>
<p>Human colon carcinoma RKO cells were obtained from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Beijing, China). RKO cells were cultured in DMEM with 10&#x0025; fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 &#x00B5;g/ml) and maintained at 37&#x00B0;C with 5&#x0025; CO<sub>2</sub> in a humidified atmosphere for 2-3 days until cells reached 80&#x0025; confluence. Cells were subsequently passaged to new plates.</p>
</sec>
<sec>
<title>Animal model</title>
<p>A total of 30 male 6&#x2013;7-week old BALB/c nude mice were purchased from the Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). Mice were acclimatized for 1 week in pathogen-free conditions at the animal laboratory of Longhua Hospital with a 12 h light/dark cycle, regulated temperature of 24&#x00B1;2&#x00B0;C and humidity of 50&#x00B1;10&#x0025;, with <italic>ad libitum</italic> access to water and animal chow.</p>
<p>Mice were injected with 2&#x00D7;10<sup>6</sup> RKO cells in 0.1 ml PBS through the tail vein. Subsequently, mice were randomly divided into 3 groups (n=10 mice/group), and intragastrically administrated with either 11.25 g/kg/0.3 ml TLBZT, 22.5 g/kg/0.3 ml TLBZT or same volume of distilled water, once a day. Following 2 months treatment, mice were sacrificed by cervical dislocation, mouse lungs were removed and weighed, and metastatic nodules on the lung surface were counted. The Longhua Hospital Animal Care and Use Committee approved all studies involving mice.</p>
</sec>
<sec>
<title>Histochemistry</title>
<p>Lung tissues were fixed in 4&#x0025; paraformaldehyde in PBS at 4&#x00B0;C overnight, embedded in paraffin and cut into 4 &#x00B5;m thick sections. Sections were then deparaffinized with xylene two times for 10 min, re-hydrated with 100, 95 and 70&#x0025; alcohol for 2 min, and stained with hematoxylin and eosin for 4 min and 1 min respectively, and mounted with xylene based mounting medium. Slides were visualized using an Olympus light microscope (Olympus Corporation, Tokyo, Japan).</p>
</sec>
<sec>
<title>Immunohistochemistry (IHC)</title>
<p>Lung tissues were fixed, embedded and cut as described above. For IHC, sections were blocked with 3&#x0025; hydrogen peroxide for 15 min at room temperature, blocked with 5&#x0025; normal goat serum (Cell Signaling Technology, Inc., Danvers, MA, USA) for 30 min at 37&#x00B0;C, and subsequently incubated with primary antibodies against LOX (1:100), integrin &#x03B1;V (1:100), integrin &#x03B2;3 (1:100), p-FAK (1:100) and HIF-1&#x03B1; (1:200) at 4&#x00B0;C overnight. Sections were then incubated with the appropriate HRP-conjugated anti-rabbit/anti mouse IgG secondary antibody (1:4,000) at 37&#x00B0;C for 30 min and visualized using 3,3-diaminobenzidine at room temperature for 3&#x2013;5 min. Sections were then counterstained with hematoxylin for 45 sec at room temperature and mounted with glass coverslips. Slides were observed using an Olympus light microscope (Olympus Corporation). Five fields at &#x00D7;200 magnification were randomly selected from each slide and analyzed using Image-Pro Plus 6.0 software (Media Cybernetics, Rockville, MD, USA).</p>
</sec>
<sec>
<title>Statistical analyses</title>
<p>Data are expressed as the mean &#x00B1; standard deviation. Differences among groups were analyzed using one-way analysis of variance followed by a least significant difference (LSD) test. P&#x2264;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>TLBZT inhibits the lung metastasis of colorectal cancer cells</title>
<p>Following treatment with TLBZT, lungs from nude mice were removed and weighed, and the number of metastatic nodules on the lung surface was counted. The results demonstrated that the number of metastatic nodules on the lung surface decreased following treatment with TLBZT in a dose-dependent manner (<xref rid="f1-ol-0-0-7206" ref-type="fig">Fig. 1A</xref>; P&#x003C;0.05). Furthermore, lung weight was significantly reduced in a dose-dependent manner following treatment with TLBZT (<xref rid="f1-ol-0-0-7206" ref-type="fig">Fig. 1B</xref>; P&#x003C;0.05). Pathology indicates that TLBZT markedly inhibited the growth of metastatic nodules in the lung (<xref rid="f1-ol-0-0-7206" ref-type="fig">Fig. 1C</xref>). Following treatment with TLBZT, no significant adverse consequences were observed, including weight loss (<xref rid="f1-ol-0-0-7206" ref-type="fig">Fig. 1D</xref>), ruffling of fur, changes in behavior and feeding (data not shown). These results suggest that TLBZT inhibits the metastasis of colorectal carcinoma without inducing toxicity.</p>
</sec>
<sec>
<title>TLBZT inhibits the expression of LOX</title>
<p>LOX is associated with the remodeling of the ECM, which serves an important role in tumor metastasis and may be a target for regulating cancer metastasis (<xref rid="b17-ol-0-0-7206" ref-type="bibr">17</xref>,<xref rid="b18-ol-0-0-7206" ref-type="bibr">18</xref>). The present study demonstrated that LOX was overexpressed in lung metastases from RKO colorectal cancer and that treatment with TLBZT significantly inhibited its expression (<xref rid="f2-ol-0-0-7206" ref-type="fig">Fig. 2</xref>; P&#x003C;0.01).</p>
</sec>
<sec>
<title>TLBZT inhibits the expression of HIF-1&#x03B1;</title>
<p>It has been demonstrated that the expression of LOX is regulated by HIF-1&#x03B1; (<xref rid="b19-ol-0-0-7206" ref-type="bibr">19</xref>); therefore, the current study determined the effect of TLBZT treatment on HIF-1&#x03B1; expression. The results demonstrated that HIF-1&#x03B1; was highly expressed in lung metastases from RKO colorectal carcinoma, but that TLBZT significantly inhibited its expression (<xref rid="f3-ol-0-0-7206" ref-type="fig">Fig. 3</xref>; P&#x003C;0.01).</p>
</sec>
<sec>
<title>TLBZT inhibits the expression of integrins &#x03B1;V and &#x03B2;3</title>
<p>Integrins serve an important role in cell-cell and cell-ECM interactions and participate in the process of tumor metastasis; thus, their inhibition may suppress cancer metastasis (<xref rid="b20-ol-0-0-7206" ref-type="bibr">20</xref>&#x2013;<xref rid="b22-ol-0-0-7206" ref-type="bibr">22</xref>). Therefore, the effects of TLBZT treatment on integrin expression were assessed. Integrins &#x03B1;V and &#x03B2;3 were overexpressed in lung metastases from RKO colorectal cancer; however, treatment with TLBZT significantly inhibited their expression (<xref rid="f4-ol-0-0-7206" ref-type="fig">Fig. 4</xref>; all P&#x003C;0.01).</p>
</sec>
<sec>
<title>TLBZT inhibits FAK phosphorylation</title>
<p>The transduction of the downstream signals of integrins are associated with the phosphorylation of FAK (<xref rid="b23-ol-0-0-7206" ref-type="bibr">23</xref>), therefore the effects of TLBZT on FAK phosphorylation were assessed using immunohistochemistry. FAK was highly phosphorylated in lung metastases from RKO colorectal cancer. However, treatment with TLBZT significantly inhibited the phosphorylation of FAK (<xref rid="f5-ol-0-0-7206" ref-type="fig">Fig. 5</xref>; P&#x003C;0.01).</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>According to TCM, the basic pathogenesis of colorectal cancer is associated with toxicity, dampness and spleen-deficiency, and the therapeutic principles of TLBZT are considered to be detoxification, overcoming dampness and tonifying the spleen (<xref rid="b9-ol-0-0-7206" ref-type="bibr">9</xref>,<xref rid="b10-ol-0-0-7206" ref-type="bibr">10</xref>). Furthermore, all the herbs contained in the TLBZT formula exhibit anti-cancer effects and are commonly used in clinical oncology. <italic>A. chinensis</italic> inhibits colorectal cancer cell proliferation and induces apoptosis via mitochondrial pathways (<xref rid="b24-ol-0-0-7206" ref-type="bibr">24</xref>). <italic>S. nigrum</italic> inhibits cell proliferation, induces autophagy and enhances the cytotoxic effect of chemotherapeutic drugs in colorectal cancer cells (<xref rid="b25-ol-0-0-7206" ref-type="bibr">25</xref>). <italic>D. indica</italic> inhibits cell proliferation, promotes cell apoptosis and arrests the cell cycle in the S-phase in cervical cancer (<xref rid="b26-ol-0-0-7206" ref-type="bibr">26</xref>).</p>
<p>Atractylenolide I, a component of <italic>A. macrocephala</italic>, is able to inhibit cell survival and induce apoptosis by upregulating the expression of caspase-2, caspase-9 and Bax, and downregulating the expression of Bcl-2 and Bcl-XL (<xref rid="b27-ol-0-0-7206" ref-type="bibr">27</xref>). Kanglaite, a Chinese herb product extracted from the <italic>Coix</italic> seed, induces apoptosis in cancer cells and is widely used to treat different types of cancer, including lung, liver and gastric cancer (<xref rid="b28-ol-0-0-7206" ref-type="bibr">28</xref>&#x2013;<xref rid="b30-ol-0-0-7206" ref-type="bibr">30</xref>). <italic>V. coloratum</italic> inhibits cell proliferation and promotes the apoptosis of colorectal cancer cells via inhibition of nuclear factor-&#x03BA;B (<xref rid="b31-ol-0-0-7206" ref-type="bibr">31</xref>). These results suggest that TLBZT is a herbal formula that exhibits anti-cancerous effects according to TCM theories and clinical practice.</p>
<p>LOX, a type of ECM-modifying enzyme, is involved in the remodeling of ECM. It is highly expressed in colorectal cancer and is considered to promote tumor metastasis (<xref rid="b17-ol-0-0-7206" ref-type="bibr">17</xref>,<xref rid="b18-ol-0-0-7206" ref-type="bibr">18</xref>,<xref rid="b32-ol-0-0-7206" ref-type="bibr">32</xref>,<xref rid="b33-ol-0-0-7206" ref-type="bibr">33</xref>). Inhibiting LOX expression impairs tumor cell metastasis, therefore LOX has become a target for cancer treatment (<xref rid="b34-ol-0-0-7206" ref-type="bibr">34</xref>,<xref rid="b35-ol-0-0-7206" ref-type="bibr">35</xref>). The expression of LOX is regulated by HIF-1&#x03B1;, which is degraded by ubiquitination in normoxic conditions. However, HIF-1&#x03B1; degradation is inhibited in hypoxic conditions and it forms heterodimers with HIF-1&#x03B2;, which activates the expression of downstream genes, including vascular endothelial growth factor and LOX, which are involved in angiogenesis and metastasis (<xref rid="b36-ol-0-0-7206" ref-type="bibr">36</xref>). The results of the present study demonstrated that LOX and HIF-1&#x03B1; are overexpressed in metastatic lesions in the lung that arise from colorectal cancer cells. Treatment with TLBZT significantly inhibited LOX and HIF-1&#x03B1; expression, suggesting that inhibition of LOX and HIF-1&#x03B1; contributes to the TLBZT-mediated prevention of colorectal cancer metastasis.</p>
<p>Integrins, consisting of &#x03B1; and &#x03B2; subtypes, are transmembrane proteins that mediate cell-cell and cell-ECM interactions (<xref rid="b37-ol-0-0-7206" ref-type="bibr">37</xref>,<xref rid="b38-ol-0-0-7206" ref-type="bibr">38</xref>). The extracellular domains of integrins &#x03B1; and &#x03B2; form a ligand binding domain for binding ligands, including fibrinogen, fibronectin and intercellular adhesion molecules (<xref rid="b37-ol-0-0-7206" ref-type="bibr">37</xref>,<xref rid="b38-ol-0-0-7206" ref-type="bibr">38</xref>). The downstream signal transduction of integrins is associated with the FAK signaling pathway and they are able to mediate the biological behavior of cells, including cell migration, invasion and metastasis (<xref rid="b23-ol-0-0-7206" ref-type="bibr">23</xref>,<xref rid="b39-ol-0-0-7206" ref-type="bibr">39</xref>). Integrin &#x03B1;V&#x03B2;3 is a heterodimer formed by the non-covalent linking of the integrin &#x03B1;V and &#x03B2;3 subunits. It is widely expressed in tumor tissues and is closely associated with tumor metastasis (<xref rid="b39-ol-0-0-7206" ref-type="bibr">39</xref>,<xref rid="b40-ol-0-0-7206" ref-type="bibr">40</xref>). Antagonizing integrin &#x03B1;V&#x03B2;3 or inhibiting its ligand, osteopontin may effectively inhibit colorectal cancer metastasis (<xref rid="b22-ol-0-0-7206" ref-type="bibr">22</xref>,<xref rid="b41-ol-0-0-7206" ref-type="bibr">41</xref>). The results of the present study indicate that integrin &#x03B1;V&#x03B2;3 is overexpressed and that FAK is highly phosphorylated in metastatic cells of RKO colorectal carcinoma. TLBZT may inhibit the expression of integrin &#x03B1;V&#x03B2;3 and the phosphorylation of FAK. These results suggest that inhibiting integrin &#x03B1;V&#x03B2;3-FAK signal transduction may induce the anti-metastatic effects observed following treatment with TLBZT in colorectal cancer.</p>
<p>To conclude, the present study demonstrated that TLBZT inhibits the metastasis of RKO colorectal cancer cells and that this may be associated with the inhibition of HIF1&#x03B1;-LOX and integrin &#x03B1;V&#x03B2;3-FAK signal transduction. These results provide a novel insight for the treatment and prevention of colorectal cancer metastasis with TLBZT.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The present study was supported by National Natural Science Foundation of China (grant nos. 81273726 and 81473625), the Program from Science and Technology Commission of Shanghai Municipality (grant no. 16401902500), the Three-year Action Program of Shanghai Municipality for Traditional Chinese Medicine (grant no. ZY3-CCCX-3-3025) and the Opening Research Fund of Shanghai Key Laboratory of Tissue Engineering (grant no. TE1401).</p>
</ack>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item><term>TLBZT</term><def><p>Teng-Long-Bu-Zhong-Tang</p></def></def-item>
<def-item><term>TCM</term><def><p>traditional Chinese medicine</p></def></def-item>
<def-item><term>LOX</term><def><p>lysyl oxidase</p></def></def-item>
<def-item><term>HIF-1&#x03B1;</term><def><p>hypoxia-inducible factor 1&#x03B1;</p></def></def-item>
<def-item><term>DMEM</term><def><p>Dulbecco&#x0027;s modified Eagle&#x0027;s medium</p></def></def-item>
<def-item><term>FAK</term><def><p>focal adhesion kinase</p></def></def-item>
<def-item><term>ECM</term><def><p>extracellular matrix</p></def></def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="b1-ol-0-0-7206"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics, 2012</article-title><source>CA Cancer J Clin</source><volume>65</volume><fpage>87</fpage><lpage>108</lpage><year>2015</year><pub-id pub-id-type="doi">10.3322/caac.21262</pub-id><pub-id pub-id-type="pmid">25651787</pub-id></element-citation></ref>
<ref id="b2-ol-0-0-7206"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogn&#x00E1;r</surname><given-names>G</given-names></name><name><surname>Ledniczky</surname><given-names>G</given-names></name><name><surname>Istv&#x00E1;n</surname><given-names>G</given-names></name><name><surname>Ondrejka</surname><given-names>P</given-names></name></person-group><article-title>Molecular mechanisms in development of colorectal cancer metastasis</article-title><source>Magy Seb</source><volume>59</volume><fpage>342</fpage><lpage>349</lpage><year>2006</year><comment>(In Hungarian)</comment><pub-id pub-id-type="pmid">17201342</pub-id></element-citation></ref>
<ref id="b3-ol-0-0-7206"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geiger</surname><given-names>TR</given-names></name><name><surname>Peeper</surname><given-names>DS</given-names></name></person-group><article-title>Metastasis mechanisms</article-title><source>Biochim Biophys Acta</source><volume>1796</volume><fpage>293</fpage><lpage>308</lpage><year>2009</year><pub-id pub-id-type="pmid">19683560</pub-id></element-citation></ref>
<ref id="b4-ol-0-0-7206"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohhara</surname><given-names>Y</given-names></name><name><surname>Fukuda</surname><given-names>N</given-names></name><name><surname>Takeuchi</surname><given-names>S</given-names></name><name><surname>Honma</surname><given-names>R</given-names></name><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Kinoshita</surname><given-names>I</given-names></name><name><surname>Dosaka-Akita</surname><given-names>H</given-names></name></person-group><article-title>Role of targeted therapy in metastatic colorectal cancer</article-title><source>World J Gastrointest Oncol</source><volume>8</volume><fpage>642</fpage><lpage>655</lpage><year>2016</year><pub-id pub-id-type="doi">10.4251/wjgo.v8.i9.642</pub-id><pub-id pub-id-type="pmid">27672422</pub-id></element-citation></ref>
<ref id="b5-ol-0-0-7206"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moorcraft</surname><given-names>SY</given-names></name><name><surname>Ladas</surname><given-names>G</given-names></name><name><surname>Bowcock</surname><given-names>A</given-names></name><name><surname>Chau</surname><given-names>I</given-names></name></person-group><article-title>Management of resectable colorectal lung metastases</article-title><source>Clin Exp Metastasis</source><volume>33</volume><fpage>285</fpage><lpage>296</lpage><year>2016</year><pub-id pub-id-type="doi">10.1007/s10585-015-9774-6</pub-id><pub-id pub-id-type="pmid">26659389</pub-id></element-citation></ref>
<ref id="b6-ol-0-0-7206"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>JJ</given-names></name><name><surname>D&#x0027;Angelica</surname><given-names>MI</given-names></name></person-group><article-title>Surgical management of hepatic metastases of colorectal cancer</article-title><source>Hematol Oncol Clin North Am</source><volume>29</volume><fpage>61</fpage><lpage>84</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.hoc.2014.09.003</pub-id><pub-id pub-id-type="pmid">25475573</pub-id></element-citation></ref>
<ref id="b7-ol-0-0-7206"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>JM</given-names></name><name><surname>Goldberg</surname><given-names>RM</given-names></name></person-group><article-title>Treatment of metastatic colorectal cancer</article-title><source>Semin Oncol</source><volume>38</volume><fpage>552</fpage><lpage>560</lpage><year>2011</year><pub-id pub-id-type="doi">10.1053/j.seminoncol.2011.05.009</pub-id><pub-id pub-id-type="pmid">21810514</pub-id></element-citation></ref>
<ref id="b8-ol-0-0-7206"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2016</article-title><source>CA Cancer J Clin</source><volume>66</volume><fpage>7</fpage><lpage>30</lpage><year>2016</year><pub-id pub-id-type="doi">10.3322/caac.21332</pub-id><pub-id pub-id-type="pmid">26742998</pub-id></element-citation></ref>
<ref id="b9-ol-0-0-7206"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>An</surname><given-names>HM</given-names></name></person-group><article-title>Traditional Chinese medicinal syndromes and treatment in colorectal cancer</article-title><source>J Cancer Ther</source><volume>3</volume><fpage>888</fpage><lpage>897</lpage><year>2012</year><pub-id pub-id-type="doi">10.4236/jct.2012.326114</pub-id></element-citation></ref>
<ref id="b10-ol-0-0-7206"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Shen</surname><given-names>KP</given-names></name></person-group><article-title>Pathogenesis and treatment of colorectal cancer in traditional Chinese medicine</article-title><source>World Sci Technol Mod Trad Chinese Med Mater Med</source><volume>14</volume><fpage>1858</fpage><lpage>1862</lpage><year>2012</year><comment>(In Chinese)</comment></element-citation></ref>
<ref id="b11-ol-0-0-7206"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>An</surname><given-names>HM</given-names></name><name><surname>Shen</surname><given-names>KP</given-names></name><name><surname>DU</surname><given-names>Q</given-names></name></person-group><article-title>Effects of Tenglong Buzhong Decoction on proliferation and apoptosis of human colon carcinoma cell line LS174T</article-title><source>Zhong Xi Yi Jie He Xue Bao</source><volume>8</volume><fpage>575</fpage><lpage>580</lpage><year>2010</year><comment>(In Chinese)</comment><pub-id pub-id-type="doi">10.3736/jcim20100611</pub-id><pub-id pub-id-type="pmid">20550881</pub-id></element-citation></ref>
<ref id="b12-ol-0-0-7206"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>An</surname><given-names>HM</given-names></name><name><surname>Shen</surname><given-names>KP</given-names></name><name><surname>Du</surname><given-names>Q</given-names></name></person-group><article-title>Senescence-inducing effects of Chinese herbal medicine Tenglong Buzhong Decoction on human colon carcinoma LS-174-T cells and the mechanism</article-title><source>Zhong Xi Yi Jie He Xue Bao</source><volume>8</volume><fpage>1048</fpage><lpage>1052</lpage><year>2010</year><comment>(In Chinese)</comment><pub-id pub-id-type="doi">10.3736/jcim20100611</pub-id><pub-id pub-id-type="pmid">21078269</pub-id></element-citation></ref>
<ref id="b13-ol-0-0-7206"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>An</surname><given-names>HM</given-names></name><name><surname>Du</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>KP</given-names></name><name><surname>Shi</surname><given-names>XF</given-names></name><name><surname>Wei</surname><given-names>MM</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><article-title>Teng-Long-Bu-Zhong-Tang, a Chinese herbal formula, enhances anticancer effects of 5-fluorouracil in CT26 colon carcinoma</article-title><source>BMC Complement Altern Med</source><volume>13</volume><fpage>128</fpage><year>2013</year><pub-id pub-id-type="doi">10.1186/1472-6882-13-128</pub-id><pub-id pub-id-type="pmid">23758730</pub-id></element-citation></ref>
<ref id="b14-ol-0-0-7206"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Shen</surname><given-names>KP</given-names></name><name><surname>Shi</surname><given-names>XF</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>MM</given-names></name></person-group><article-title>Root of <italic>Actinidia chinensis</italic> induces anoikis in colon carcinoma RKO cells</article-title><source>Chin J Exp Tradit Med Formul</source><volume>19</volume><fpage>242</fpage><lpage>245</lpage><year>2013</year><comment>(In Chinese)</comment></element-citation></ref>
<ref id="b15-ol-0-0-7206"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Shen</surname><given-names>KP</given-names></name><name><surname>Shi</surname><given-names>XF</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>MM</given-names></name></person-group><article-title>Experimental research of RKO cell anoikis induced by <italic>Duchesnea indica</italic> in human colon cancer</article-title><source>World J Integr Trad West Med</source><volume>8</volume><fpage>69</fpage><lpage>72</lpage><year>2013</year><comment>(In Chinese)</comment></element-citation></ref>
<ref id="b16-ol-0-0-7206"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>An</surname><given-names>HM</given-names></name><name><surname>Shen</surname><given-names>KP</given-names></name><name><surname>Shi</surname><given-names>XF</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>MM</given-names></name></person-group><article-title>Effect of <italic>Solanum nigrum</italic> on human colon carcinoma RKO cells</article-title><source>Zhong Yao Cai</source><volume>36</volume><fpage>958</fpage><lpage>961</lpage><year>2013</year><comment>(In Chinese)</comment><pub-id pub-id-type="pmid">24380285</pub-id></element-citation></ref>
<ref id="b17-ol-0-0-7206"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>Ge</surname><given-names>G</given-names></name></person-group><article-title>Lysyl oxidase, extracellular matrix remodeling and cancer metastasis</article-title><source>Cancer Microenviron</source><volume>5</volume><fpage>261</fpage><lpage>273</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s12307-012-0105-z</pub-id><pub-id pub-id-type="pmid">22528876</pub-id></element-citation></ref>
<ref id="b18-ol-0-0-7206"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>TR</given-names></name><name><surname>Gartland</surname><given-names>A</given-names></name><name><surname>Erler</surname><given-names>JT</given-names></name></person-group><article-title>Lysyl oxidase, a targetable secreted molecule involved in cancer metastasis</article-title><source>Cancer Res</source><volume>76</volume><fpage>188</fpage><lpage>192</lpage><year>2016</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-2306</pub-id><pub-id pub-id-type="pmid">26732355</pub-id></element-citation></ref>
<ref id="b19-ol-0-0-7206"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Di</surname><given-names>W</given-names></name></person-group><article-title>Hypoxia inducible factor 1&#x03B1;-mediated LOX expression correlates with migration and invasion in epithelial ovarian cancer</article-title><source>Int J Oncol</source><volume>42</volume><fpage>1578</fpage><lpage>1588</lpage><year>2013</year><pub-id pub-id-type="doi">10.3892/ijo.2013.1878</pub-id><pub-id pub-id-type="pmid">23545606</pub-id></element-citation></ref>
<ref id="b20-ol-0-0-7206"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felding-Habermann</surname><given-names>B</given-names></name></person-group><article-title>Integrin adhesion receptors in tumor metastasis</article-title><source>Clin Exp Metastasis</source><volume>20</volume><fpage>203</fpage><lpage>213</lpage><year>2003</year><pub-id pub-id-type="doi">10.1023/A:1022983000355</pub-id><pub-id pub-id-type="pmid">12741679</pub-id></element-citation></ref>
<ref id="b21-ol-0-0-7206"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>Q</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Xiong</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><article-title>Anoikis induction and metastasis suppression by a new integrin &#x03B1;v&#x03B2;3 inhibitor in human melanoma cell line M21</article-title><source>Invest New Drugs</source><volume>29</volume><fpage>666</fpage><lpage>673</lpage><year>2011</year><pub-id pub-id-type="doi">10.1007/s10637-010-9616-y</pub-id><pub-id pub-id-type="pmid">21170668</pub-id></element-citation></ref>
<ref id="b22-ol-0-0-7206"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinmuth</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Ahmad</surname><given-names>SA</given-names></name><name><surname>Fan</surname><given-names>F</given-names></name><name><surname>Stoeltzing</surname><given-names>O</given-names></name><name><surname>Parikh</surname><given-names>AA</given-names></name><name><surname>Bucana</surname><given-names>CD</given-names></name><name><surname>Gallick</surname><given-names>GE</given-names></name><name><surname>Nickols</surname><given-names>MA</given-names></name><name><surname>Westlin</surname><given-names>WF</given-names></name><name><surname>Ellis</surname><given-names>LM</given-names></name></person-group><article-title>Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice</article-title><source>Cancer Res</source><volume>63</volume><fpage>2079</fpage><lpage>2087</lpage><year>2003</year><pub-id pub-id-type="pmid">12727823</pub-id></element-citation></ref>
<ref id="b23-ol-0-0-7206"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>SK</given-names></name><name><surname>Schlaepfer</surname><given-names>DD</given-names></name></person-group><article-title>Integrin-regulated FAK-Src signaling in normal and cancer cells</article-title><source>Curr Opin Cell Biol</source><volume>18</volume><fpage>516</fpage><lpage>523</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.ceb.2006.08.011</pub-id><pub-id pub-id-type="pmid">16919435</pub-id></element-citation></ref>
<ref id="b24-ol-0-0-7206"><label>24</label><element-citation publication-type="conference"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Shi</surname><given-names>RJ</given-names></name></person-group><article-title>Ethanol extract from radix of <italic>Actinidia chinensis</italic> inhibits cell proliferation and indeuces apoptosis in human colon carcinoma cell line LoVo</article-title><source>World Chin J Digest</source><volume>20</volume><fpage>1657</fpage><lpage>1661</lpage><year>2012</year><comment>(In Chinese)</comment></element-citation></ref>
<ref id="b25-ol-0-0-7206"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>CJ</given-names></name><name><surname>Wang</surname><given-names>CK</given-names></name><name><surname>Tai</surname><given-names>CJ</given-names></name><name><surname>Lin</surname><given-names>YF</given-names></name><name><surname>Lin</surname><given-names>CS</given-names></name><name><surname>Jian</surname><given-names>JY</given-names></name><name><surname>Chang</surname><given-names>YJ</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name></person-group><article-title>Aqueous extract of <italic>Solanum nigrum</italic> leaves induces autophagy and enhances cytotoxicity of cisplatin, doxorubicin, docetaxel, and 5-fluorouracil in human colorectal carcinoma cells</article-title><source>Evid Based Complement Alternat Med</source><volume>2013</volume><fpage>514719</fpage><year>2013</year><pub-id pub-id-type="doi">10.1155/2013/514719</pub-id><pub-id pub-id-type="pmid">23843876</pub-id></element-citation></ref>
<ref id="b26-ol-0-0-7206"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title><italic>Duchesnea</italic> phenolic fraction inhibits in vitro and in vivo growth of cervical cancer through induction of apoptosis and cell cycle arrest</article-title><source>Exp Biol Med (Maywood)</source><volume>234</volume><fpage>74</fpage><lpage>83</lpage><year>2009</year><pub-id pub-id-type="doi">10.3181/0806-RM-204</pub-id><pub-id pub-id-type="pmid">19064947</pub-id></element-citation></ref>
<ref id="b27-ol-0-0-7206"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>X</given-names></name></person-group><article-title>Anti-tumor effects of atractylenolide I isolated from <italic>Atractylodes macrocephala</italic> in human lung carcinoma cell lines</article-title><source>Molecules</source><volume>18</volume><fpage>13357</fpage><lpage>13368</lpage><year>2013</year><pub-id pub-id-type="doi">10.3390/molecules181113357</pub-id><pub-id pub-id-type="pmid">24172243</pub-id></element-citation></ref>
<ref id="b28-ol-0-0-7206"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Xi</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Kou</surname><given-names>X</given-names></name></person-group><article-title>Kanglaite injection combined with chemotherapy versus chemotherapy alone in the treatment of advanced non-small cell lung carcinoma</article-title><source>J Cancer Res Ther</source><volume>10</volume><supplement>Suppl 1</supplement><fpage>S46</fpage><lpage>S51</lpage><year>2014</year><pub-id pub-id-type="doi">10.4103/0973-1482.139758</pub-id></element-citation></ref>
<ref id="b29-ol-0-0-7206"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>F</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Mulati</surname></name><name><surname>Wu</surname><given-names>T</given-names></name></person-group><article-title>Kanglaite injection combined with hepatic arterial intervention for unresectable hepatocellular carcinoma: A meta-analysis</article-title><source>J Cancer Res Ther</source><volume>10</volume><supplement>Suppl 1</supplement><fpage>S38</fpage><lpage>S41</lpage><year>2014</year><pub-id pub-id-type="doi">10.4103/0973-1482.139753</pub-id></element-citation></ref>
<ref id="b30-ol-0-0-7206"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>YP</given-names></name><name><surname>Huang</surname><given-names>XE</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>YY</given-names></name><name><surname>Wu</surname><given-names>XY</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>LH</given-names></name></person-group><article-title>Clinical safety and efficacy of Kanglaite<sup>&#x00AE;</sup> (<italic>Coix</italic> seed oil) injection combined with chemotherapy in treating patients with gastric cancer</article-title><source>Asian Pac J Cancer Prev</source><volume>13</volume><fpage>5319</fpage><lpage>5321</lpage><year>2012</year><pub-id pub-id-type="doi">10.7314/APJCP.2012.13.9.4773</pub-id><pub-id pub-id-type="pmid">23244156</pub-id></element-citation></ref>
<ref id="b31-ol-0-0-7206"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>SM</given-names></name><name><surname>Ni</surname><given-names>SM</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title>Mistletoe induces apoptosis by down-regulating the constitutive activation of nuclear factor-kB in HCT116 cells</article-title><source>Chin J Clin Pharm Ther</source><volume>13</volume><fpage>730</fpage><lpage>734</lpage><year>2008</year><comment>(In Chinese)</comment></element-citation></ref>
<ref id="b32-ol-0-0-7206"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Roh</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Cho</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>JC</given-names></name></person-group><article-title>Differential expression of the LOX family genes in human colorectal adenocarcinomas</article-title><source>Oncol Rep</source><volume>22</volume><fpage>799</fpage><lpage>804</lpage><year>2009</year><pub-id pub-id-type="doi">10.3892/or_00000502</pub-id><pub-id pub-id-type="pmid">19724858</pub-id></element-citation></ref>
<ref id="b33-ol-0-0-7206"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>ST</given-names></name><name><surname>Weston</surname><given-names>CJ</given-names></name><name><surname>Hepburn</surname><given-names>E</given-names></name><name><surname>Damery</surname><given-names>S</given-names></name><name><surname>Hejmadi</surname><given-names>RK</given-names></name><name><surname>Morton</surname><given-names>DG</given-names></name><name><surname>Middleton</surname><given-names>G</given-names></name><name><surname>Ismail</surname><given-names>T</given-names></name><name><surname>Adams</surname> <given-names>DH</given-names></name></person-group><article-title>Evaluation of serum lysyl oxidase as a blood test for colorectal cancer</article-title><source>Eur J Surg Oncol</source><volume>40</volume><fpage>731</fpage><lpage>738</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.ejso.2013.10.023</pub-id><pub-id pub-id-type="pmid">24246612</pub-id></element-citation></ref>
<ref id="b34-ol-0-0-7206"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>TR</given-names></name><name><surname>Erler</surname><given-names>JT</given-names></name></person-group><article-title>Lysyl oxidase in colorectal cancer</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><volume>305</volume><fpage>G659</fpage><lpage>G666</lpage><year>2013</year><pub-id pub-id-type="doi">10.1152/ajpgi.00425.2012</pub-id><pub-id pub-id-type="pmid">24008360</pub-id></element-citation></ref>
<ref id="b35-ol-0-0-7206"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bondareva</surname><given-names>A</given-names></name><name><surname>Downey</surname><given-names>CM</given-names></name><name><surname>Ayres</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Boyd</surname><given-names>SK</given-names></name><name><surname>Hallgrimsson</surname><given-names>B</given-names></name><name><surname>Jirik</surname><given-names>FR</given-names></name></person-group><article-title>The lysyl oxidase inhibitor, beta-aminopropionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells</article-title><source>PLoS One</source><volume>4</volume><fpage>e5620</fpage><year>2009</year><pub-id pub-id-type="doi">10.1371/journal.pone.0005620</pub-id><pub-id pub-id-type="pmid">19440335</pub-id></element-citation></ref>
<ref id="b36-ol-0-0-7206"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finger</surname><given-names>EC</given-names></name><name><surname>Giaccia</surname><given-names>AJ</given-names></name></person-group><article-title>Hypoxia, inflammation, and the tumor microenvironment in metastatic disease</article-title><source>Cancer Metastasis Rev</source><volume>29</volume><fpage>285</fpage><lpage>293</lpage><year>2010</year><pub-id pub-id-type="doi">10.1007/s10555-010-9224-5</pub-id><pub-id pub-id-type="pmid">20393783</pub-id></element-citation></ref>
<ref id="b37-ol-0-0-7206"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>K</given-names></name><name><surname>Rivera-Nieves</surname><given-names>J</given-names></name><name><surname>Sandborn</surname><given-names>WJ</given-names></name><name><surname>Shattil</surname><given-names>S</given-names></name></person-group><article-title>Integrin-based therapeutics: Biological basis, clinical use and new drugs</article-title><source>Nat Rev Drug Discov</source><volume>15</volume><fpage>173</fpage><lpage>183</lpage><year>2016</year><pub-id pub-id-type="doi">10.1038/nrd.2015.10</pub-id><pub-id pub-id-type="pmid">26822833</pub-id></element-citation></ref>
<ref id="b38-ol-0-0-7206"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwamoto</surname><given-names>DV</given-names></name><name><surname>Calderwood</surname><given-names>DA</given-names></name></person-group><article-title>Regulation of integrin-mediated adhesions</article-title><source>Curr Opin Cell Biol</source><volume>36</volume><fpage>41</fpage><lpage>47</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.ceb.2015.06.009</pub-id><pub-id pub-id-type="pmid">26189062</pub-id></element-citation></ref>
<ref id="b39-ol-0-0-7206"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsay</surname><given-names>AG</given-names></name><name><surname>Marshall</surname><given-names>JF</given-names></name><name><surname>Hart</surname><given-names>IR</given-names></name></person-group><article-title>Integrin trafficking and its role in cancer metastasis</article-title><source>Cancer Metastasis Rev</source><volume>26</volume><fpage>567</fpage><lpage>578</lpage><year>2007</year><pub-id pub-id-type="doi">10.1007/s10555-007-9078-7</pub-id><pub-id pub-id-type="pmid">17786537</pub-id></element-citation></ref>
<ref id="b40-ol-0-0-7206"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>AR</given-names></name><name><surname>Veeravagu</surname><given-names>A</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Hou</surname><given-names>LC</given-names></name><name><surname>Tse</surname><given-names>V</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment</article-title><source>Recent Pat Anticancer Drug Discov</source><volume>2</volume><fpage>143</fpage><lpage>158</lpage><year>2007</year><pub-id pub-id-type="doi">10.2174/157489207780832469</pub-id><pub-id pub-id-type="pmid">18221059</pub-id></element-citation></ref>
<ref id="b41-ol-0-0-7206"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wai</surname><given-names>PY</given-names></name><name><surname>Mi</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Sarraf-Yazdi</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Marroquin</surname><given-names>CE</given-names></name><name><surname>Clary</surname><given-names>B</given-names></name><name><surname>Kuo</surname><given-names>PC</given-names></name></person-group><article-title>Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis</article-title><source>Carcinogenesis</source><volume>26</volume><fpage>741</fpage><lpage>751</lpage><year>2005</year><pub-id pub-id-type="doi">10.1093/carcin/bgi027</pub-id><pub-id pub-id-type="pmid">15661802</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-ol-0-0-7206" position="float">
<label>Figure 1.</label>
<caption><p>Effect of TLBZT on the metastasis of colorectal cancer to the lungs. Male BALB/c nude mice were injected 2&#x00D7;10<sup>6</sup> RKO cells through the tail vein and received intragastric administration of 11.25 g/kg/0.3 ml or 22.5 g/kg/0.3 ml TLBZT, or the same volume of distilled water once a day. Following 2 months treatment, mouse lungs were removed. (A) The number of metastatic nodules on the lung surface were counted. (B) Lung weights were measured (C) Hematoxylin and eosin staining indicating metastasis in the lung at &#x00D7;200 magnification. (D) The body weights of the mice in each group were compared prior to and following treatment. &#x002A;P&#x003C;0.05 and &#x002A;&#x002A;P&#x003C;0.01 vs. control group. TLBZT, Teng-Long-Bu-Zhong-Tang.</p></caption>
<graphic xlink:href="ol-14-06-7767-g00.tif"/>
</fig>
<fig id="f2-ol-0-0-7206" position="float">
<label>Figure 2.</label>
<caption><p>The effect of TLBZT on LOX expression. (A) The expression of LOX in lung metastatic lesions was detected by immunohistochemistry and observed using a microscope at &#x00D7;200 magnification. (B) The mean optical density of LOX was determined using Image-Pro Plus 6.0 software and expressed as a fold of the control &#x002A;&#x002A;P&#x003C;0.01 vs. control. TLBZT, Teng-Long-Bu-Zhong-Tang; LOX, lysyl oxidase.</p></caption>
<graphic xlink:href="ol-14-06-7767-g01.tif"/>
</fig>
<fig id="f3-ol-0-0-7206" position="float">
<label>Figure 3.</label>
<caption><p>Effects of TLBZT on HIF-1&#x03B1; expression. (A) The expression of HIF-1&#x03B1; in lung metastatic lesions was detected by immunohistochemistry and observed using a microscope at &#x00D7;200 magnification. (B) The mean optical density of HIF-1&#x03B1; was determined using Image-Pro Plus 6.0 software and expressed as a fold of the control &#x002A;&#x002A;P&#x003C;0.01 vs. control. TLBZT, Teng-Long-Bu-Zhong-Tang; HIF-1&#x03B1;, hypoxia-inducible factor 1&#x03B1;.</p></caption>
<graphic xlink:href="ol-14-06-7767-g02.tif"/>
</fig>
<fig id="f4-ol-0-0-7206" position="float">
<label>Figure 4.</label>
<caption><p>Effects of TLBZT on the expression of integrins. (A) The expression of integrins &#x03B1;V and &#x03B2;3 in lung metastatic lesions were detected by immunohistochemistry and observed using a microscope at &#x00D7;200 magnification. (B) The mean optical density of integrins &#x03B1;V and &#x03B2;3 was analyzed using Image-Pro Plus 6.0 software and expressed as a fold of the control. &#x002A;&#x002A;P&#x003C;0.01 vs. control. TLBZT, Teng-Long-Bu-Zhong-Tang.</p></caption>
<graphic xlink:href="ol-14-06-7767-g03.tif"/>
</fig>
<fig id="f5-ol-0-0-7206" position="float">
<label>Figure 5.</label>
<caption><p>Effects of TLBZT on FAK phosphorylation. (A) The phosphorylation of FAK in lung metastatic lesions was detected by immunohistochemistry and observed using a microscope at &#x00D7;200 magnification. (B) The mean optical density of FAK phosphorylation was determined with Image-Pro Plus 6.0 software and expressed as a fold of the control. &#x002A;&#x002A;P&#x003C;0.01 vs. control. TLBZT, Teng-Long-Bu-Zhong-Tang; FAK, focal adhesion kinase.</p></caption>
<graphic xlink:href="ol-14-06-7767-g04.tif"/>
</fig>
</floats-group>
</article>
